Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 486 participants.

Also called NCT01101009

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 486 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01101009
  • EudraCT 2009-012966-30
Other papers using this trial's data
  • The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension Advances in therapy, 2013-12 DOI, PubMed 24293132, PMC3898428 PubMed links an erratum for this paper. Erratum: PMID 25712918 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01101009. Randomized; double masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2012-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
Condition
Hypertension
Intervention (Drug)
Perindopril + amlodipine + if necessary, hydrochlorothiazide
Intervention (Drug)
olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct01101009
Content hash
9f9e987d61591e8f5184e0f77ef9f03a9be7b998219c7584fb0db4bb2f2d5143